logo
Share SHARE
FONT-SIZE Plus   Neg

Ranbaxy Obtains Approval To Market Ran-Rosuvastatin In Canada - Quick Facts

Ranbaxy Pharmaceuticals Canada Inc. or RPCI, a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced that RPCI has received approval from Health Canada to manufacture and market RAN-Rosuvastatin tablets to the Canadian healthcare system. Rosuvastatin is a HMG-COA Reductase Inhibitor (cholesterol-lowering medication). Brand sales of Crestorin Canada were $742.2 million.

"The finished dosage form was developed, and will be manufactured within RLL's Health Canada approved facilities located in India. We anticipate making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies are available to meet market demand," said Paul Drake, President and General Manager of RPCI.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Online retail giant Amazon is launching technical teams with full-time employees, but with 30 hour a week work schedule, the Washington Post reported. The program could help boost the image of Amazon, which has faced criticism for intense work conditions earlier. Taxi-hailing company Uber and its rival Careem has suspended their services in Abu Dhabi, the capital of the United Arab Emirates, since Saturday, reports said. Uber said the move was temporary, and did not explain the reason for suspension of services. Even after two years of thoroughly searching across the Indian Ocean, using modern technologies and devices, there is no clue about the Malaysian airline that vanished on March 8, 2014.
comments powered by Disqus
Follow RTT